Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)

Immunoglobulin G (IgG) replacement therapy is a standard treatment for patients with primary immunodeficiency diseases (PIDs). Hizentra®, a 20% human subcutaneous IgG (SCIG), is approved for biweekly administration for PIDs. The aim of the multicenter IBIS study was to prospectively investigate the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Immunol
Glavni autori: Vultaggio, Alessandra, Azzari, Chiara, Ricci, Silvia, Martire, Baldassarre, Palladino, Valentina, Gallo, Vera, Pecoraro, Antonio, Pignata, Claudio, Spadaro, Giuseppe, Graziani, Simona, Moschese, Viviana, Trizzino, Antonino, Boggia, Giorgio Maria, Matucci, Andrea
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2018
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6061090/
https://ncbi.nlm.nih.gov/pubmed/29951948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-018-0528-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items